Krystal Biotech (KRYS) Return on Capital Employed (2017 - 2026)
Krystal Biotech recorded quarterly Return on Capital Employed of 14.21% in Q1 2026, up 4.33% quarter-over-quarter from 13.62% in Q4 2025, and up 318.0% year-over-year from 3.4% in Q1 2025.
Krystal Biotech's Return on Capital Employed history runs 10 years deep, the most recent figure standing at 14.21% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 318.0% year-over-year to 14.21%; the TTM figure through Mar 2026 stood at 14.21% (up 318.0% YoY), while the FY2025 annual figure was 14.77%, up 690.0% from the prior year.
- Return on Capital Employed came in at 14.21% for Q1 2026 at Krystal Biotech, up from 13.62% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 14.42% in Q3 2025 to a low of 28.19% in Q1 2023.
- A 5-year average of 6.62% and a median of 8.56% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 1365 bps in 2022 and jumped 2401 bps in 2024, its largest moves.
- Krystal Biotech's Return on Capital Employed stood at 26.96% in 2022, then surged by 47 bps to 14.21% in 2023, then jumped by 150 bps to 7.17% in 2024, then jumped by 90 bps to 13.62% in 2025, then gained by 4 bps to 14.21% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 14.21%, 13.62%, and 14.42% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Krystal Biotech | 9.05 Bn | 8.23 Bn | 110.03 Mn | 14.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.21% |
| Dec 31, 2025 | 13.62% |
| Sep 30, 2025 | 14.42% |
| Jun 30, 2025 | 13.67% |
| Mar 31, 2025 | 11.02% |
| Dec 31, 2024 | 7.17% |
| Sep 30, 2024 | 3.21% |
| Jun 30, 2024 | -2.56% |
| Mar 31, 2024 | -8.56% |
| Dec 31, 2023 | -14.21% |
| Sep 30, 2023 | -20.81% |
| Jun 30, 2023 | -26.21% |
| Mar 31, 2023 | -28.19% |
| Dec 31, 2022 | -26.96% |
| Sep 30, 2022 | -23.59% |
| Jun 30, 2022 | -20.27% |
| Mar 31, 2022 | -18.56% |
| Dec 31, 2021 | -13.31% |
| Sep 30, 2021 | -13.81% |
| Jun 30, 2021 | -11.96% |
| Mar 31, 2021 | -11.26% |
| Dec 31, 2020 | -11.16% |
| Mar 31, 2020 | -11.49% |
| Dec 31, 2019 | -10.60% |
| Sep 30, 2019 | -9.78% |
| Jun 30, 2019 | -11.36% |
| Mar 31, 2019 | -12.72% |
| Dec 31, 2018 | -14.41% |
| Sep 30, 2018 | -19.03% |
| Jun 30, 2018 | -18.01% |
| Mar 31, 2018 | -13.56% |
| Dec 31, 2017 | -9.40% |